Bu öğeden alıntı yapmak, öğeye bağlanmak için bu tanımlayıcıyı kullanınız: http://hdl.handle.net/11452/29661
Başlık: Synaptogenesis: Modulation by availability of membrane phospholipid precursors
Yazarlar: Uludağ Üniversitesi/Tıp Fakültesi/Eczacılık Anabilim Dalı.
0000-0003-2918-5064
Cansev, Mehmet
M-9071-2019
8872816100
Anahtar kelimeler: Neurosciences & neurology
Synaptogenesis
Uridine
Choline
Docosahexaenoic acid
Cognition
Alzheimer's disease
Cdp-choline levels
Alzheimers-disease
Fatty-acid
Dietary supplementation
Functional expression
Brain phospholipids
Synaptic proteins
Learning-ability
Plasma choline
Yayın Tarihi: 24-May-2016
Yayıncı: Humana Press
Atıf: Cansev, M. (2016). "Synaptogenesis: Modulation by availability of membrane phospholipid precursors". NeuroMolecular Medicine, 18(3), 426-440.
Özet: Phospholipids are the main constituents of brain membranes. Formation of new membranes requires that uridine, the omega-3 polyunsaturated fatty acids such as docosahexaenoic acid (DHA), and choline, the three circulating precursors of major phospholipids, interact via the Kennedy pathway. Supplementation of laboratory rodents with uridine, DHA and choline enhances the amount of brain membranes as well as synaptic proteins and increases the number of dendritic spines, the essential cytological precursor of new synapses. Hence, the newly formed membranes are utilized for synaptogenesis which underlies increased synaptic functioning evidenced by enhanced neurotransmission and cognition. In addition, this supplementation ameliorates the degeneration in a rat model of Parkinson's disease and mouse models of Alzheimer's disease (AD) when used in combination with several vitamins and cofactors. Hence, accumulating evidence shows that increasing the availability of phospholipid precursors, vitamins and cofactors to the brain through dietary supplementation enhances the formation of new synapses and provides protection under neurodegenerative conditions. The combination has been tested in clinical trials and a medication has been marketed for early-stage AD patients.
URI: https://doi.org/10.1007/s12017-016-8414-x
https://link.springer.com/article/10.1007/s12017-016-8414-x
http://hdl.handle.net/11452/29661
ISSN: 1535-1084
1559-1174
Koleksiyonlarda Görünür:Scopus
Web of Science

Bu öğenin dosyaları:
Bu öğeyle ilişkili dosya bulunmamaktadır.


DSpace'deki bütün öğeler, aksi belirtilmedikçe, tüm hakları saklı tutulmak şartıyla telif hakkı ile korunmaktadır.